South Korea · Delayed Price · Currency is KRW T&R Biofab Statistics
Total Valuation
T&R Biofab has a market cap or net worth of KRW 96.28 billion. The enterprise value is 119.01 billion.
| Market Cap | 96.28B |
| Enterprise Value | 119.01B |
Important Dates
The next estimated earnings date is Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
T&R Biofab has 47.66 million shares outstanding. The number of shares has increased by 54.52% in one year.
| Current Share Class | 47.66M |
| Shares Outstanding | 47.66M |
| Shares Change (YoY) | +54.52% |
| Shares Change (QoQ) | -24.97% |
| Owned by Insiders (%) | 15.17% |
| Owned by Institutions (%) | 2.79% |
| Float | 40.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.24 |
| PB Ratio | 4.50 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 1.41.
| Current Ratio | 1.03 |
| Quick Ratio | 0.72 |
| Debt / Equity | 1.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.23 |
| Interest Coverage | -0.99 |
Financial Efficiency
Return on equity (ROE) is -146.06% and return on invested capital (ROIC) is -6.30%.
| Return on Equity (ROE) | -146.06% |
| Return on Assets (ROA) | -4.04% |
| Return on Invested Capital (ROIC) | -6.30% |
| Return on Capital Employed (ROCE) | -8.08% |
| Weighted Average Cost of Capital (WACC) | 8.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.32 |
| Inventory Turnover | 5.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.55% in the last 52 weeks. The beta is 0.45, so T&R Biofab's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -49.55% |
| 50-Day Moving Average | 2,707.80 |
| 200-Day Moving Average | 2,629.01 |
| Relative Strength Index (RSI) | 31.96 |
| Average Volume (20 Days) | 353,924 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, T&R Biofab had revenue of KRW 29.73 billion and -31.21 billion in losses. Loss per share was -811.88.
| Revenue | 29.73B |
| Gross Profit | 8.55B |
| Operating Income | -6.02B |
| Pretax Income | -31.21B |
| Net Income | -31.21B |
| EBITDA | -1.16B |
| EBIT | -6.02B |
| Loss Per Share | -811.88 |
Balance Sheet
The company has 7.40 billion in cash and 30.13 billion in debt, with a net cash position of -22.73 billion or -476.92 per share.
| Cash & Cash Equivalents | 7.40B |
| Total Debt | 30.13B |
| Net Cash | -22.73B |
| Net Cash Per Share | -476.92 |
| Equity (Book Value) | 21.42B |
| Book Value Per Share | 451.28 |
| Working Capital | 467.22M |
Cash Flow
In the last 12 months, operating cash flow was -2.31 billion and capital expenditures -2.53 billion, giving a free cash flow of -4.84 billion.
| Operating Cash Flow | -2.31B |
| Capital Expenditures | -2.53B |
| Depreciation & Amortization | 4.86B |
| Net Borrowing | -25.28B |
| Free Cash Flow | -4.84B |
| FCF Per Share | -101.47 |
Margins
Gross margin is 28.74%, with operating and profit margins of -20.24% and -104.97%.
| Gross Margin | 28.74% |
| Operating Margin | -20.24% |
| Pretax Margin | -104.97% |
| Profit Margin | -104.97% |
| EBITDA Margin | -3.90% |
| EBIT Margin | -20.24% |
| FCF Margin | n/a |
Dividends & Yields
T&R Biofab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.52% |
| Shareholder Yield | -54.52% |
| Earnings Yield | -32.42% |
| FCF Yield | -5.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 29, 2025. It was a forward split with a ratio of 1.2.
| Last Split Date | Oct 29, 2025 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
T&R Biofab has an Altman Z-Score of -1.66 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.66 |
| Piotroski F-Score | 3 |